Acer Therapeutics (ACER) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Climate Environment Environmental Intensity Lifecycle Materials Nature Offset Packaging Pandemic Raw Materials Toxic Waste Water Access African American Asian Benefits Black Charitable Community Culture Customer Cyber Cybersecurity Death Demographic Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Resources Injury Latinx LGBTQ Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Social Society Stakeholder Supplier Supply Chain Training Union Volunteer Women Workers Workforce Assessment Assurance Audit Bonus Chronic Class Action Lawsuit Classified Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Materiality Mission Oversee Oversight Plaintiff Poison Pill Proxy Contest Purpose Quality Standard Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Targets Tax Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The virtual Annual Meeting of Stockholders of Acer Therapeutics Inc. (the “Company”) was held on May 20, 2022 (the “Annual Meeting”). Three proposals were submitted to stockholders as described in the Proxy Statement for the Annual Meeting and were approved by the Company’s stockholders at the Annual Meeting. The proposals and the results of the stockholder votes are as follows.

1. Proposal to elect five directors to serve until the 2023 annual meeting or until their successors are duly elected and qualified:

	For	Withheld	Broker Non-Votes


Stephen J. Aselage	6,409,689	27,519	3,268,875
Jason Amello	6,420,321	16,887	3,268,875
John M. Dunn	6,397,566	39,642	3,268,875
Michelle Griffin	6,411,530	25,678	3,268,875
Chris Schelling	6,420,727	16,481	3,268,875

2. Proposal to approve, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers:

For	Against	Abstain	Broker Non-Votes


6,286,230	136,464	14,514	3,268,875

3. Proposal to ratify the appointment of BDO USA, LLP as independent auditors for the fiscal year ending December 31, 2022:

For	Against	Abstain	Broker Non-Votes


9,689,232	14,192	2,659	0